---
title: Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
nct_id: NCT00092196
overall_status: COMPLETED
phase: PHASE3
sponsor: Merck Sharp & Dohme LLC
study_type: INTERVENTIONAL
primary_condition: Nausea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00092196.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00092196"
ct_last_update_post_date: 2017-05-05
last_seen_at: "2026-05-12T06:59:28.514Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

**Official Title:** Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy

**NCT ID:** [NCT00092196](https://clinicaltrials.gov/study/NCT00092196)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 820
- **Lead Sponsor:** Merck Sharp & Dohme LLC
- **Conditions:** Nausea, Vomiting, Breast Neoplasms
- **Start Date:** 2002-12-01
- **Completion Date:** 2004-12-01
- **CT.gov Last Update:** 2017-05-05

## Brief Summary

The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.
* Patient must have completed participation in the main study for this protocol.

Exclusion Criteria:

* Patient has a central nervous system malignancy.
* Patient will receive radiation to the abdomen or pelvis.
```

## Interventions

- **MK0869, aprepitant / Duration of Treatment: 3 days** (DRUG)

## Primary Outcomes

- **Safety and tolerability**

## Secondary Outcomes

- **Assessment of adverse experiences using the National Cancer Institute (NCI) criteria**

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00092196.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00092196*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*